Th9 cells are a subset of CD4+ Th cells that produce the pleiotropic cytokine IL-9. IL-9/Th9 can function as both positive and negative regulators of immune response, but the role of IL-9/Th9 in tumor immunity is unknown. We examined the role of IL-9/Th9 in a model of pulmonary melanoma in mice. Lack of IL-9 enhanced tumor growth, while tumor-specific Th9 cell treatment promoted stronger antitumor responses in both prophylactic and therapeutic models. Th9 cells also elicited strong host antitumor CD8+ CTL responses by promoting Ccl20/Ccr6-dependent recruitment of DCs to the tumor tissues. Subsequent tumor antigen delivery to the draining LN resulted in CD8+ T cell priming. In agreement with this model, Ccr6 deficiency abrogated the Th9 cell–mediated antitumor response. Our data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell–based cancer immunotherapy may be a promising therapeutic approach.
Yong Lu, Sungyoul Hong, Haiyan Li, Jungsun Park, Bangxing Hong, Lijuan Wang, Yuhuan Zheng, Zhiqiang Liu, Jingda Xu, Jin He, Jing Yang, Jianfei Qian, Qing Yi
Title and authors | Publication | Year |
---|---|---|
USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity
B Hong, H Li, Y Lu, M Zhang, Y Zheng, J Qian, Q Yi |
Molecular Cancer | 2014 |
The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment
J Zhou, Y Xiang, T Yoshimura, K Chen, W Gong, J Huang, Y Zhou, X Yao, X Bian, JM Wang |
BioMed Research International | 2014 |
Reducing CD73 Expression by IL1 -Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors
S Chatterjee, K Thyagarajan, P Kesarwani, JH Song, M Soloshchenko, J Fu, SR Bailey, C Vasu, AS Kraft, CM Paulos, XZ Yu, S Mehrotra |
Cancer research | 2014 |
Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers
Y Lu, B Hong, H Li, Y Zheng, M Zhang, S Wang, J Qian, Q Yi |
Proceedings of the National Academy of Sciences | 2014 |
Anticancer Tc9 cells
Y Lu, Q Wang, Q Yi |
OncoImmunology | 2014 |
CIMT 2014: Next waves in cancer immunotherapy - Report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany
M Diken, S Boegel, C Grunwitz, LM Kranz, K Reuter, N de Roemer, F Vascotto, M Vormehr, S Kreiter |
Human Vaccines & Immunotherapeutics | 2014 |
The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells
F Végran, H Berger, R Boidot, G Mignot, M Bruchard, M Dosset, F Chalmin, C Rébé, V Dérangère, B Ryffel, M Kato, A Prévost-Blondel, F Ghiringhelli, L Apetoh |
Nature Immunology | 2014 |
TGFβ in T cell biology and tumor immunity: Angel or devil?
E Tu, PZ Chia, W Chen |
Cytokine & Growth Factor Reviews | 2014 |
USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses
Q Zou, J Jin, H Hu, HS Li, S Romano, Y Xiao, M Nakaya, X Zhou, X Cheng, P Yang, G Lozano, C Zhu, SS Watowich, SE Ullrich, SC Sun |
Nature Immunology | 2014 |
Human TH9 Cells Are Skin-Tropic and Have Autocrine and Paracrine Proinflammatory Capacity
C Schlapbach, A Gehad, C Yang, R Watanabe, E Guenova, JE Teague, L Campbell, N Yawalkar, TS Kupper, RA Clark |
Science Translational Medicine | 2014 |
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy
J Park, H Li, M Zhang, Y Lu, B Hong, Y Zheng, J He, J Yang, J Qian, Q Yi |
Cancer Immunology, Immunotherapy | 2014 |
Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression
W Liao, R Spolski, P Li, N Du, EE West, M Ren, S Mitra, WJ Leonard |
Proceedings of the National Academy of Sciences | 2014 |
Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma
J Zhang, W Wang, QR Geng, L Wang, XQ Chen, CC Liu, Y Lv |
PloS one | 2014 |
Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses
X Yao, Q Kong, X Xie, J Wang, N Li, Y Liu, B Sun, Y Li, G Wang, W Li, S Qu, H Zhao, D Wang, X Liu, Y Zhang, L Mu, H Li |
Immunology | 2014 |
Inhibition of Adaptive Immunity by IL9 Can Be Disrupted to Achieve Rapid T-cell Sensitization and Rejection of Progressive Tumor Challenges
DB Hoelzinger, AL Dominguez, PA Cohen, SJ Gendler |
Cancer research | 2014 |